Monu Khanna, MD, discusses common medications, non-drug strategies, and holistic approaches to improve outcomes.
The FDA approved updated dosing for donanemab in early Alzheimer disease, reducing ARIA-E risk by 41% without compromising efficacy.
The Fujirebio in-vitro diagnostic has shown positive and negative predictive values of 92% and 97%, respectively, for early AD detection and will be offered by end of summer.
GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.
Richard Rosenfeld, MD, MPH, MBA, explains how clinical guidelines for diabetes remission from the American College of Lifestyle Medicine differ from and augment existing recommendations.
Your daily dose of the clinical news you may have missed.
Dr Khanna discusses dosing challenges, metabolic issues, and potential complications from medications like acetaminophen.
Discover essential clinical insights on Alzheimer disease screening in primary care, eczema treatments, and the latest in cancer detection and diet impacts on CHD risk.
New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.
Exercise and strength/balance training are keys to protect against falls but careful assessments at each clinic visit can uncover many other risks you'll want to address.